Publications by authors named "Charles Landen"

Claim this Profile
I
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Benoit You, Charles Anderson, Sabrina Chiara Cecere, Aurore Carrot, Tashanna Myers, Charles Landen

Gynecol Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential for opportunistic salpingectomy to reduce ovarian cancer in women undergoing non-gynecologic surgery.
Ian C Cook, Sarah E Podwika, Peter T Hallowell, Mark R Conaway, Charles N Landen

Gynecol Oncol Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Malecot drain in the management of a vaginal cuff dehiscence: A case report and review of the literature.
Bria Murray, Caleigh E Smith, Jorge Alsina, Megan Howard, Charles Landen

Gynecol Oncol Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study.
Paulette Mhawech-Fauceglia, Denis McCarthy, Akiko Tonooka, Giovanni Scambia, Yolanda Garcia, Charles Landen

Gynecol Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles.
Kevin Elias, Urszula Smyczynska, Konrad Stawiski, Zuzanna Nowicka, James Webber, Charles Landen

Nat Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
Charles N Landen, Luciana Molinero, Habib Hamidi, Jalid Sehouli, Austin Miller

Clin Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy.
Alexandra R Harris, Savieay Esparza, Mohammad S Azimi, Robert Cornelison, Francesca N Azar, Charles N Landen

Front Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Premal H Thaker, Liz Y Han, Aparna A Kamat, Jesusa M Arevalo, Rie Takahashi, Charles N Landen

Nat Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
Gururaj Shivange, Tanmoy Mondal, Evan Lyerly, Sanchita Bhatnagar, Charles N Landen

Cell Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer.
Robert Cornelison, Kuntal Biswas, Danielle C Llaneza, Alexandra R Harris, Nisha G Sosale, Charles N Landen

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
Aparna A Kamat, Mavis Fletcher, Lynn M Gruman, Peter Mueller, Adriana Lopez, Charles N Landen

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Monoclonal Antibody Targeting Cancer-Specific Plectin Has Potent Antitumor Activity in Ovarian Cancer.
Samantha M Perez, Julien Dimastromatteo, Charles N Landen, Kimberly A Kelly

Cells· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer.
John S Lazo, Elizabeth R Sharlow, Robert Cornelison, Duncan J Hart, Danielle C Llaneza, Charles N Landen

Biomolecules· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.
Burthia E Booker, Adam D Steg, Stefan Kovac, Charles N Landen, Hope M Amm

Cancer Biol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
C Bethan Powell, Ramey D Littell, Charles N Landen, Sharmila Pramanik, Isabella C Hamilton

Gynecol Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Jung Mi Byun, Dae Sim Lee, Charles N Landen, Da Hyun Kim, Young Nam Kim

Acta Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
Ronald J Buckanovich, Gordon Rustin, Shitanshu Uppal, Alexander B Olawaiye, Joseph L Kelley, Charles N Landen

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
Stephen Shang, Jiekun Yang, Amir A Jazaeri, Alexander James Duval, Turan Tufan, Charles N Landen

Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Focal Adhesion Kinase Targeting Using Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Jyotsnabaran Halder, Aparna A Kamat, Charles N Landen, Liz Y Han, Susan K Lutgendorf

Clin Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Ilana Chefetz, Edward Grimley, Kun Yang, Linda Hong, Ekaterina V Vinogradova, Charles Landen

Cell Rep· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer.
Edith Emmings, Sally Mullany, Zenas Chang, Charles N Landen, Stig Linder

Int J Mol Sci· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kelly M Kreitzburg, Samuel C Fehling, Charles N Landen, Tracy L Gamblin, Rebecca B Vance

Cancer Lett· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
Gururaj Shivange, Karol Urbanek, Piotr Przanowski, Justin S A Perry, James Jones, Charles N Landen

Cancer Cell· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Rebecca C Arend, Angelina I Londoño-Joshi, Abhishek Gangrade, Ashwini A Katre, Chandrika Kurpad, Charles N Landen

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis